Treatment for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) can vary greatly. Dr. John Mascarenhas breaks down the treatment types and the goals of treatment for each type of myeloproliferative neoplasm (MPN).
Dr. John Mascarenhas is Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai. Learn more about Dr. Mascarenhas, here: [ Ссылка ].
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: powerfulpatients.org/connect
An Overview of ET, PV and MF Treatment Options
Теги
Dr. John MascarenhasMPNMyeloproliferative NeoplasmPolycythemia VeraMyelofibrosisEssential ThrombocythemiaMFPVETphlebotomyJakafibone marrow biopsyMPL mutationCalreticulin mutationCALRJAK2V617F mutationfedratinibpacritinibthrombotic riskblood clotaspirinenlarged spleensplenomegalyInterferonJAK inhibitorcytoreductive therapyHydroxyureastem cell transplantanemiaAnagrelideBiologic therapyhematocritInrebicErythropoietinEPODanazol